Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Poorly Differentiated Neuroendocrine Carcinomas”

42 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 42 results

Testing effectiveness (Phase 2)Study completedNCT02113800
What this trial is testing

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Who this might be right for
Poorly Differentiated Malignant Neuroendocrine CarcinomaNeuroendocrine Carcinoma, Grade 3Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3+2 more
AIO-Studien-gGmbH 40
Testing effectiveness (Phase 2)Looking for participantsNCT07016230
What this trial is testing

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

Who this might be right for
Metastatic/Locally Advanced Small-Cell Lung CancerMetastatic/Locally Advanced Poorly Differentiated NECMetastatic/Locally Advanced High-grade MTC
Gustave Roussy, Cancer Campus, Grand Paris
Early research (Phase 1)Study completedNCT00019019
What this trial is testing

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerKidney Cancer+6 more
National Institutes of Health Clinical Center (CC) 70
Testing effectiveness (Phase 2)Looking for participantsNCT04325425
What this trial is testing

Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

Who this might be right for
Neuroendocrine Carcinoma
Centre Hospitalier Universitaire Dijon 218
Testing effectiveness (Phase 2)Active Not RecruitingNCT02595424
What this trial is testing

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Who this might be right for
Gastric Neuroendocrine CarcinomaIntestinal Neuroendocrine CarcinomaPancreatic Neuroendocrine Carcinoma
ECOG-ACRIN Cancer Research Group 67
Not applicableUnknownNCT03896958
What this trial is testing

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

Who this might be right for
Cancer, All TypesCancer of LiverCancer of Stomach+42 more
SpeciCare 1,000
Early research (Phase 1)Ended earlyNCT01769222
What this trial is testing

Ipilimumab and Local Radiation for Selected Solid Tumors

Who this might be right for
Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+31 more
Stanford University 3
Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Not applicableWithdrawnNCT00378781
What this trial is testing

Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection

Who this might be right for
Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT03630120
What this trial is testing

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Who this might be right for
Thyroid CancerThyroid Cancer, MedullaryDifferentiated Thyroid Cancer+3 more
H. Lee Moffitt Cancer Center and Research Institute 6
Testing effectiveness (Phase 2)Ended earlyNCT01215578
What this trial is testing

Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

Who this might be right for
Neuroendocrine TumorsPancreatic NeoplasmsAdvanced Disease+1 more
Assistance Publique - Hôpitaux de Paris 33
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Very early researchEnded earlyNCT00499733
What this trial is testing

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Who this might be right for
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Testing effectiveness (Phase 2)Study completedNCT03278405
What this trial is testing

Avelumab in G3 NEC

Who this might be right for
Neuroendocrine Carcinoma
Sunnybrook Health Sciences Centre 10
Early research (Phase 1)Study completedNCT00049296
What this trial is testing

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Who this might be right for
Cancer
Case Comprehensive Cancer Center 26
Testing effectiveness (Phase 2)Study completedNCT01480986
What this trial is testing

IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC

Who this might be right for
Progression Free Survival of the Treatment
Peking University 40
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Not applicableActive Not RecruitingNCT04069299
What this trial is testing

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

Who this might be right for
Neuroendocrine Carcinoma
H. Lee Moffitt Cancer Center and Research Institute 30
Early research (Phase 1)Study completedNCT00006368
What this trial is testing

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid Tumor+5 more
Novartis Pharmaceuticals 60
Load More Results
40
116